Investment and M&A transaction comps
Biotech & Pharma Investment & M&A Transaction Comps
Biotech, pharma, therapeutics, platform technology and life-sciences asset transactions. Revenue and EBITDA multiples are shown where meaningful; milestone, royalty, stage and asset-basis notes matter more for many pre-commercial deals.
| Year | Transactions | Priced | Median EV or valuation / revenue | Median EV or valuation / EBITDA |
|---|---|---|---|---|
| 2026 | 4 | 2 | - | - |
Sortable transaction comps
Biotech transaction table
Rows with reported value
5 / 9
Acquisition EV, USD
USD 6.0B
Investment EV, USD
-
Median EV / revenue
5.2x
Selected comparison set
Saved in this browser only. Nothing is written to FundComb data.
Choose transactions from the table to build a quick comparison set.
9 shown of 9 matching transactions. Click any transaction row for more detail.
Values are 100% enterprise values. Multiples divide EV by full-company revenue or EBITDA. Reported prices are assumed to be EV; explicit partial-stake prices are grossed up as estimates. Amounts paid are tracked separately.
| Select for comparison | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Dersimelagon rights Control | 2026-08-18 | LEO Pharma | USD 435M Consideration | 435 | - | - | Denmark / Japan | Confirmed 3 sources | ||
| 2026-07-13 | Servier | Undisclosed | Undisclosed | - | - | - | Confirmed 2 sources | |||
| 2026-07-06 | Altaris LLC | USD 600M Consideration | 600 | - | - | - | Confirmed 1 source | |||
| Tubulis Control | 2026-05-21 | Gilead Sciences | Undisclosed | Undisclosed | - | - | Germany | Confirmed 1 source | ||
| Aerie Pharmaceuticals, Inc. Control (100%) | 2022-08-22 | Alcon Research, Ltd. | USD 750M Enterprise Value | 750 | 4.4x | - | United States | Estimated 1 source | ||
| Flexion Therapeutics Control | 2021-10-11 | Pacira BioSciences | Undisclosed | Undisclosed | - | 11.0x | United States | Confirmed 1 source | ||
| Aimmune Therapeutics Control | 2020-08-31 | Sociétés des Produits Nestlé S.A. / Nestlé Health Science | USD 2.6B | 2,600 | - | - | United States | Estimated 1 source | ||
| ITM Isotope Technologies Munich SE Control (100%) | - | Telix Pharmaceuticals Limited | USD 1.6B Enterprise Value | 1,650 | 6.0x | - | Germany | Confirmed 3 sources | ||
| E-Pharma Trento Control (100%) | - | Wise Equity | Undisclosed | Undisclosed | - | - | Italy | Confirmed 1 source |